Meeting
2017 Gastrointestinal Cancers Symposium
A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER.
Authors
Akihito Tsuji
Department of Clinical Oncology, Kagawa University Faculty of Medicine, Kagawa, Japan
Akihito Tsuji , Yu Sunakawa , Wataru Ichikawa , Yutaro Kubota , Mitsugu Kochi , Takashi Sekikawa , Tamotsu Sagawa , Masahito Kotaka , Masato Nakamura , Ken Shimada , Toshiki Masuishi , Hironaga Satake , Taichi Yabuno , Taichi Yoshida , Masahiro Goto , Hirofumi Ota , Yoshihiro Okita , Masahiro Takeuchi , Masashi Fujii , Toshifusa Nakajima
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
000018217
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract TPS818)
DOI
10.1200/JCO.2017.35.4_suppl.TPS818
Abstract #
TPS818
Poster Bd #
O18
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
First Author: Takanori Watanabe
Poster
2018 Gastrointestinal Cancers Symposium
A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study.
First Author: Shigenori Kadowaki
Poster
2014 ASCO Annual Meeting
STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Johanna C. Bendell
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando